Avelox in Complicated Skin and Skin Structure Infections

Bayer6,127 enrolled

Overview

This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions. Specifically investigated are the improvement of clinical symptoms and the duration until infection improvement and cure.Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) treated with Avelox can be documented. The observation period for each subject covers the treatment period with Avelox. For each patient, the physician documents data at an initial visit and one or two follow-up visit(s) in line with routine practice.

Study Type

OBSERVATIONAL

Enrollment

6,127

Conditions

Skin Diseases, Bacterial

Interventions

Moxifloxacin (Avelox, BAY12-8039)DRUG

400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information

Eligibility

Sex: ALLMin age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any patient with a diagnosis of complicated skin and skin structure infection (cSSSI) and for whom the decision was made by the attending physician to start treatment with Avelox before inclusion into and independent of the study. Exclusion Criteria: * Exclusion criteria are those specified in the local product information.

Locations (12)

Unnamed facility

Many Locations, Austria

Unnamed facility

Many Locations, Bulgaria

Unnamed facility

Many Locations, Egypt

Unnamed facility

Many Locations, Germany

Outcomes

Primary Outcomes

Efficacy: course of severity of infection, course of clinical signs and symptoms, duration until improvement, duration until recovery, duration until wound closure, overall assessment of efficacy by the physician, reuse of Avelox

Time frame: last documented follow-up visit, according to the respective praxis routine

Secondary Outcomes

Adverse events collection

Time frame: during entire study course, according to the respective praxis routine

Overall assessment of tolerability by the physician

Time frame: last documented follow-up visit, according to the respective praxis routine

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.